Trade STRATEC SE NA O.N. - SBS CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.26
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.01802 %(-€3.60)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01802%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.00421 %(-€0.84)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00421%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01802 %
  (-€3.60)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00421 %
  (-€0.84)

Key Stats

• Prev. Close: 24.02
• Open: 23.77
• 1-Year Change: -14.4%
• Day's Range: 23.27 - 24.27

Trade STRATEC SE NA O.N. - SBS

About Stratec SE

Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

Financial summary

BRIEF: For the nine months ended 30 September 2021, StratecSE revenues increased 26% to EUR225.4M. Net income beforeextraordinary items increased 95% to EUR36.3M. Revenuesreflect Instrumentation segment increase of 30% toEUR109.9M, Diatron segment increase of 25% to EUR35.2M. Netincome benefited from General administration expensesdecrease of 19% to EUR12.1M (expense), Research anddevelopment expenses decrease of 30% to EUR5.7M (expense).

Equity composition

07/2006, Scrip Issue, 1.994 new shares for every 1 shareheld.